View Older Stories View More Recent Stories
-
Eli Lilly (LLY) PT Raised to $1,500 at Citi
-
Freedom Capital Markets Downgrades Eli Lilly (LLY) to Hold
-
Eli Lilly upgraded at Leerink on 'multiple waves' of obesity drug adoption
-
Leerink Partners Upgrades Eli Lilly (LLY) to Outperform
-
TD Cowen Reiterates Buy Rating on Eli Lilly (LLY) Post US Government Deal
-
Lilly names new executives to lead neuroscience and immunology units
-
Eli Lilly agrees with government to cap obesity drug costs at $50 monthly
-
Trump administration reaches GLP-1 drug pricing deals with Eli Lilly and Novo Nordisk - White House
-
Eli Lilly & Co. (LLY) call put ratio 3.1 calls to 1 put with a focus on November 7 weekly calls
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put amid price movement
-
Stocks expected to have increasing option volume: LLY NVO VKTX NVAX ARM QCOM LYFT APP HOOD DASH MCK TKO AZN ABNB SNAP VST
-
Eli Lilly (LLY) PT Raised to $1,100 at BMO Capital
-
Deutsche Bank: 'We think the pricing overhangs for GLP1s look relatively benign and favorable to LLY'
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
Trump admin talking to Lilly and Novo Nordisk to offer weight-loss drugs at reduced prices via TrumpRx - WSJ
-
Lilly and Novo near White House deal on obesity drug prices - Endpoints News
-
Lilly plans $3 billion manufacturing facility in Netherlands
-
Bernstein on Eli Lilly (LLY): 'Stock Limited Near-Term by Poli(cy)tics'
-
Eli Lilly (LLY) PT Raised to $976 at Jefferies
-
Eli Lilly raises annual revenue guidance amid strong weight-loss drug demand
-
Eli Lilly & Co. (LLY) Tops Q3 EPS by 113c; raises guidance
-
Eli Lilly poised for strong quarter despite profit hit from one-time charge
-
Eli Lilly & Co. (LLY) call put ratio 2.2 calls to 1 put into quarter results
-
Eli Lilly invests $1.2 billion to expand Puerto Rico manufacturing site
-
LillyDirect partners with Walmart for Zepbound pickup option
-
Eli Lilly builds supercomputer with NVIDIA for drug discovery
-
Lilly receives FDA approval for single-injection Omvoh maintenance dosing
-
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield
-
Lilly's Omvoh shows bowel urgency improvements in ulcerative colitis study
-
Eli Lilly submits data for EBGLYSS eight-week dosing to FDA
-
Eli Lilly (LLY) PT Raised to $930 at BMO Capital
-
Nektar Therapeutics (NKTR) PT Raised to $105 at B.Riley
-
Nektar Therapeutics (NKTR) Strength Attributed to Rumor
-
Lilly's Verzenio shows survival benefit in early breast cancer study
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Amid GLP-1 Pricing Uncertainty
-
Eli Lilly & Co. (LLY) call put ratio 4.6 calls to 1 put into headlines
-
Stocks expected to have increasing option volume: LLY NVO VKTX AXP OZK TFC SLB FITB HBAN ALLY CME RGTI QUBT IONQ
-
After-hours movers: CSX Corp, Interactive Brokers, Novo Nordisk, Lilly
-
Eli Lilly Shares Fall 2.7%, Novo Drops 2.8%; Trump: Ozempic, Fatloss Drug Prices To Come Down 'pretty Fast'
-
Citizens Reiterates Market Outperform Rating on ProQR Therapeutics N.V. (PRQR)
-
Erste Group Upgrades Eli Lilly (LLY) to Buy, 'expect Eli Lilly to gain market share relative to its peers'
-
Lilly to present Verzenio survival data at ESMO meeting
-
Abbvie (ABBV) PT Raised to $284 at Piper Sandler
-
TD Cowen says this is 'a must-own stock'
-
Eli Lilly (LLY) PT Raised to $948 at Guggenheim
-
Citizens Reiterates Market Outperform Rating on Terns Pharmaceuticals (TERN)
-
Former FDA vaccine regulator Peter Marks joins Eli Lilly
-
Lilly reports four-year remission data for ulcerative colitis drug
-
TD Cowen Calls Eli Lilly (LLY) 'A Must-Own Stock'
-
Eli Lilly & Co. (LLY) call put ratio 2.4 calls to 1 put with a focus on a spreader of November 850 calls
